HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zheng, Y. Articles by Powell, J. D. Search for Related Content PubMed PubMed Citation Articles by Zheng, Y. Articles by Powell, J. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

A Role for Mammalian Target of Rapamycin in Regulating T Cell Activation versus Anergy¹

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Medical Institutions, Baltimore, MD 21231

Whether TCR engagement leads to activation or tolerance is determined by the concomitant delivery of multiple accessory signals, cytokines, and environmental cues. In this study, we demonstrate that the mammalian target of rapamycin (mTOR) integrates these signals and determines the outcome of TCR engagement with regard to activation or anergy. In vitro, Ag recognition in the setting of mTOR activation leads to full immune responses, whereas recognition in the setting of mTOR inhibition results in anergy. Full T cell activation is associated with an increase in the phosphorylation of the downstream mTOR target S6 kinase 1 at Thr⁴²¹/Ser⁴²⁴ and an increase in the mTOR-dependent cell surface expression of transferrin receptor (CD71). Alternatively, the induction of anergy results in markedly less S6 kinase 1 Thr⁴²¹/Ser⁴²⁴ phosphorylation and CD71 surface expression. Likewise, the reversal of anergy is associated not with proliferation, but rather the specific activation of mTOR. Importantly, T cells engineered to express a rapamycin-resistant mTOR construct are resistant to anergy induction caused by rapamycin. In vivo, mTOR inhibition promotes T cell anergy under conditions that would normally induce priming. Furthermore, by examining CD71 surface expression, we are able to distinguish and differentially isolate anergic and activated T cells in vivo. Overall, our data suggest that by integrating environmental cues, mTOR plays a central role in determining the outcome of Ag recognition.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by National Institutes of Health Grants; National Institute of Allergy and Infection Diseases Grant 5K22AI1773 and National Cancer Institute Grant RO1CA98109.

² Address correspondence and reprint requests to Dr. Jonathan D. Powell, Department of Oncology-Immunology/Hematopoiesis, Johns Hopkins School of Medicine, 1650 Orleans Street, CRB 443, Baltimore, MD 21231. E-mail address: Poweljo{at}jhmi.edu

³ Abbreviations used in this paper: mTOR, mammalian target of rapamycin; CSA, cyclosporin A; PCC, pigeon cytochrome c; RR-mTOR, rapamycin-resistant mTOR; S6K-1, S6 kinase-1; SFA, sanglifehrin A; WT-mTOR, wild-type mTOR.

This article has been cited by other articles:

				R. J. Salmond, J. Emery, K. Okkenhaug, and R. Zamoyska MAPK, Phosphatidylinositol 3-Kinase, and Mammalian Target of Rapamycin Pathways Converge at the Level of Ribosomal Protein S6 Phosphorylation to Control Metabolic Signaling in CD8 T Cells J. Immunol., December 1, 2009; 183(11): 7388 - 7397. [Abstract] [Full Text] [PDF]

				Y. Zheng, G. M. Delgoffe, C. F. Meyer, W. Chan, and J. D. Powell Anergic T Cells Are Metabolically Anergic J. Immunol., November 15, 2009; 183(10): 6095 - 6101. [Abstract] [Full Text] [PDF]

				A. D. Wells New Insights into the Molecular Basis of T Cell Anergy: Anergy Factors, Avoidance Sensors, and Epigenetic Imprinting J. Immunol., June 15, 2009; 182(12): 7331 - 7341. [Abstract] [Full Text] [PDF]

				J. T. Lin, N. B. Lineberry, M. G. Kattah, L. L. Su, P. J. Utz, C. G. Fathman, and L. Wu Naive CD4 T Cell Proliferation Is Controlled by Mammalian Target of Rapamycin Regulation of GRAIL Expression J. Immunol., May 15, 2009; 182(10): 5919 - 5928. [Abstract] [Full Text] [PDF]

				R. Zhang, N. Zhang, and D. L. Mueller Casitas B-Lineage Lymphoma b Inhibits Antigen Recognition and Slows Cell Cycle Progression at Late Times during CD4+ T Cell Clonal Expansion J. Immunol., October 15, 2008; 181(8): 5331 - 5339. [Abstract] [Full Text] [PDF]

				R. E. Mills, K. R. Taylor, K. Podshivalova, D. B. McKay, and J. M. Jameson Defects in Skin {gamma}{delta} T Cell Function Contribute to Delayed Wound Repair in Rapamycin-Treated Mice J. Immunol., September 15, 2008; 181(6): 3974 - 3983. [Abstract] [Full Text] [PDF]